We have a long track record of assisting biopharma companies in developing coherent & credible value narratives to explain where, when, and how new products deliver value to patients, providers, and payers.
We have extensive experience in the area of evidence planning, identifying, producing, and weaving together the threads needed to create the fabric of coherent and credible value narratives and HEOR strategies.
Early economic modeling is a key component of HEOR planning, ensuring that resources are deployed in areas where information gaps are most problematic and the expected return on investment in evidence generation activities is greatest.
Evidence synthesis—including systematic & targeted literature reviews, meta-analyses, indirect treatment comparisons, and network meta-analyses—is often a mission-critical component of HEOR evidence generation and value narratives.
At PAI, we are keenly aware that data from RCTs often represent an overlooked opportunity to answer key HEOR questions, and we have extensive experience in highlighting where and how to collect data in planned trials and/or mine data from completed studies in creative ways.
Modeling and simulation
Our track record in modeling and simulation spans more than 40 years, ranging from early economic models to inform “go/no-go” decisions to complex models designed to meet increasingly stringent evidence requirements of payers and HTA bodies.
Real-world data analytics
Our team of highly experienced professionals has decades of experience working with different types of real-world evidence, and the know-how to deploy such information in both novel and rigorous ways to answer questions important to value positioning and market access.